Decreasing the amount of dexamethasone that individuals with newly diagnosed multiple myeloma received did not affect survival, according to a secondary analysis of completed clinical trials.
Nearly 70% of patients treated with dexamethasone required dose reductions due to grade 3 toxicities.
“After 1 to 2 months, I would argue for the vast majority of patients who are getting any form of a modern triplet or quadruplet, the benefits of dexamethasone start to fade into oblivion, and the risks [associated with] dexamethasone remain constant,” Rahul Banerjee, MD, FACP, assistant
